064 Novel Technologies for Assessing Lipoprotein Sub-fractions
NHLBI SBIR/STTR Contract Topic
(Fast-Track proposals will be accepted.)
Number of anticipated awards: 1-2
Identifying cardiovascular risk factors and
understanding the contribution of those risk factors
for cardiovascular disease is critical. Identifying
individuals at very high risk for CVD and aggressive
intervention are a critical factor to minimize the
population wide CVD burden. Determining low density
lipoprotein (LDL) as well as high density
lipoprotein (HDL) particle size distribution may
provide additional predictive power to LDL or HDL
cholesterol measurement alone to estimate an
individual’s risk for CVD. Current systems that can
quantify the lipoprotein sub-fractions are labor
intensive and need long turnaround time and thus are
not practical for routine clinical applications.
Offerors will develop novel technologies for
accurate, high throughput measurement of lipoprotein
sub-fractions and use the developed technology to
study the value of diagnostic performance in CVD.
Phase I proposals should address initial
development and feasibility testing of novel
lipoprotein sub-fraction measurements.
Phase II proposals should focus on the optimization
and standardization of the technology and also
compare with existing methods. It is expected that
the developed technology be used to study the value
of lipoprotein sub- fraction measurements in CVD
For more information, contact OTAC.
Return to NHLBI
Last Updated December 2011